Cardiac fibrosis

ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease

Retrieved on: 
Wednesday, October 25, 2023
Inflammasome, HADHA, Plasma, Mitochondrion, ASC, Pulmonary fibrosis, Myocardial injury after non-cardiac surgery, Obesity, Human, Inflammation, Research, Mouse, Cardiac fibrosis, Scar, Magnetic resonance imaging, Therapy, Super Meat Boy, Cardiovascular disease, Pharmaceutical industry, Meat, NLRP3, Diabetes

Inflammasome ASC localized in the heart’s mitochondria participates in NLRP3 inflammasome formation and activation based on mouse data.

Key Points: 
  • Inflammasome ASC localized in the heart’s mitochondria participates in NLRP3 inflammasome formation and activation based on mouse data.
  • “The research published in Diabetes demonstrates that ASC in the heart’s mitochondria facilitates NLRP3 inflammasome assembly and activation leading to damaging inflammation and myocardial fibrosis associated with obesity.
  • By inhibiting ASC, IC 100 blocks formation of NLRP3 and other types of inflammasomes to block initiation of the inflammatory cascade.
  • To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here .

Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day

Retrieved on: 
Thursday, October 19, 2023
Week, Science, Research, LVEF, Cytokinetics, Hypertrophic cardiomyopathy, Cardiology, Safety, Cardiac fibrosis, Patient, Heart failure, SAN, Pharmaceutical industry, Heart failure with preserved ejection fraction, HCM

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) will provide an update on the company’s cardiac myosin inhibitor programs and plans to build a specialty cardiology franchise today at its virtual Investor and Analyst Day, “New Horizons in Hypercontractility.” The company plans to review the broad development program for aficamten and present new long-term data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM) and highlight commercial readiness activities in advance of the potential approval and launch of aficamten. The company will also present new preclinical data for CK-4021586 (CK-586), a cardiac myosin inhibitor in development for the potential treatment of patients with heart failure with preserved ejection fraction (HFpEF). Today’s event will also feature perspectives from leading physician experts and a patient advocate living with hypertrophic cardiomyopathy (HCM).

Key Points: 
  • Today’s event will also feature perspectives from leading physician experts and a patient advocate living with hypertrophic cardiomyopathy (HCM).
  • “Cytokinetics is advancing plans to build a specialty cardiology franchise anchored by aficamten.
  • At today’s Investor & Analyst Day, a panel of leading physician experts in the treatment of HCM will discuss perspectives on the evolving HCM landscape.
  • Registered attendees may access the virtual event platform by visiting the Investor & Media section of the Cytokinetics website at www.cytokinetics.com .

Neu REFIX β-glucan reduces muscle fibrosis in Duchenne muscular dystrophy MDX mice, in joint research with Dr. Yoshitsugu Aoki, NCNP, Tokyo, Japan.

Retrieved on: 
Tuesday, October 17, 2023
Science, Biotechnology, Research, Health, Hospitals, Genetics, Vitamins, Supplements, Clinical Trials, Molecular Therapy, Congress, Multimedia, Death, Plasma, Beta-glucan, National Center for Health Research, Scientific Reports, Inflammation, Trial of the century, DMD, Safety, NSAA, Disease, Pulmonary fibrosis, Patient, Allergen, Nature, Heart failure, Head, Neurology, Cardiac fibrosis, Clinical trial, MDX, Mouse, Duchenne muscular dystrophy, Pathology, Fibrosis, Multisystemic smooth muscle dysfunction syndrome, Myositis, MRC, Dietary supplement, Pharmaceutical industry, Psychiatry

This research was undertaken jointly with the team of Dr Yoshitsugu Aoki , Head, Dept.

Key Points: 
  • This research was undertaken jointly with the team of Dr Yoshitsugu Aoki , Head, Dept.
  • of Molecular Therapy, National Center for Neurology and Psychiatry (NCNP), Tokyo, Japan, a pioneer in developing solutions to DMD such as exon skipping therapy .
  • The findings published in Scientific Reports, a publication by Nature portfolio also reported a reduction in muscle inflammation, which precedes fibrosis and muscle dysfunction, leading gradually to respiratory muscle failure followed by lung dysfunction, cardiac fibrosis, heart failure and premature death.
  • With additional experiments in MDX mice underway , as more data evolves, that may be value adding to recommend Neu REFIX β-glucan to DMD patients, said Dr Yoshitsugu Aoki.

Broad Institute of MIT and Harvard announces a new research alliance with Novo Nordisk to identify therapeutic targets for type 2 diabetes and cardiometabolic diseases

Retrieved on: 
Wednesday, September 6, 2023
Heart, Insulin resistance, Broad Institute, Failure, Drug development, MGH, Diabetes, Novo Nordisk, Genetics, Cardiac fibrosis, Cardiovascular disease, Type 2 diabetes, Research, Genomics, MIT, Harvard University, Organization, Development, Patient, Machine learning, Cardiology, Therapy, Gene, Disease, Medical device, Pharmaceutical industry

CAMBRIDGE, Mass., Sept. 6, 2023 /PRNewswire/ -- The Broad Institute of MIT and Harvard today announced a new research alliance with Novo Nordisk aimed at addressing critical unmet clinical needs in diabetes and cardiometabolic diseases. The collaboration will focus on advancing three programs over the next three years. Two programs aim to identify drug targets for clinically important subtypes of type 2 diabetes, which affects more than 37 million people in the United States alone, and one program aims to unravel the genetic roots of cardiac fibrosis, or scarring of the heart, which occurs in many cardiovascular diseases that can lead to heart dysfunction and failure.

Key Points: 
  • Broad Institute announces a new research alliance with Novo Nordisk aimed at diabetes and cardiometabolic diseases.
  • "Diabetes and cardiac fibrosis are two conditions in dire need of new therapies," said Todd Golub, director of the Broad Institute.
  • The two diabetes programs will aim to identify therapeutic targets for both non-weight mediated insulin resistance and loss of beta cell function.
  • We look forward to leveraging resources generated by the community to produce what's really needed for treating these diseases."

IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease

Retrieved on: 
Thursday, July 6, 2023
Research, FDA, Diabetes, Stem Cells, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Danon disease, Duchenne muscular dystrophy, Heart failure, Vertex, Cardiac fibrosis, Food, Cardiac muscle, Facial muscles, Patient, Cardiomyopathy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IPS, Disease, Pharmaceutical industry, HEART, Duchenne

IPS HEART, a privately held cell therapy company advancing its stem cell platform to develop new skeletal muscle and cardiac muscle generation treatments for Duchenne muscular dystrophy (a rare disease) and heart failure, today announced that the U.S. Food and Drug Administration (FDA) awarded a third Rare Pediatric Drug Designation (RPDD) for its product candidate, ISX9-CPC, for treatment of cardiomyopathy associated with Danon disease.

Key Points: 
  • IPS HEART, a privately held cell therapy company advancing its stem cell platform to develop new skeletal muscle and cardiac muscle generation treatments for Duchenne muscular dystrophy (a rare disease) and heart failure, today announced that the U.S. Food and Drug Administration (FDA) awarded a third Rare Pediatric Drug Designation (RPDD) for its product candidate, ISX9-CPC, for treatment of cardiomyopathy associated with Danon disease.
  • ISX9-CPC stem cell therapeutic candidate is designed to create new functional human heart muscle along with reducing cardiac fibrosis.
  • The FDA previously awarded RPDDs for ISX9-CPC and GIVI-MPC for the treatment of Duchenne muscular dystrophy.
  • Separately, the FDA granted Orphan Drug Designation for its GIVI-MPC for the treatment of Duchenne muscular dystrophy.

HAYA Therapeutics Adds Douglas L. Mann, M.D. as Chairperson of Clinical Advisory Board

Retrieved on: 
Tuesday, June 20, 2023
Cardiology, Biotechnology, FDA, Other Health, Diabetes, Health, Pharmaceutical, Research, Genetics, Science, Clinical Trials, Tissue, Heart, The New England Journal of Medicine, Heart failure, JAMA Cardiology, Research fellow, Cardiac fibrosis, European Society of Cardiology, RNA, Multimedia, Inflammation, Lung, NEJM, Chairperson, Heart Failure Society of America, Ada, Journal, Cell biology, Patient, Washington University School of Medicine, BPS Barbara Wilson Lifetime Achievement Award, Liver, Temple University School of Medicine, Principal, American College, Lafayette College, SA, Therapy, III, HCM, Tumor microenvironment, Physiology, Pharmaceutical industry, Medical device, Biology, Medicine

HAYA Therapeutics, SA , a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs, today announced that Douglas L. Mann, M.D.

Key Points: 
  • HAYA Therapeutics, SA , a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs, today announced that Douglas L. Mann, M.D.
  • is joining as Chairperson of the company’s Clinical Advisory Board.
  • is joining as Chairperson of the company’s Clinical Advisory Board.
  • Members of HAYA’s Clinical Advisory Board:
    “Through their platform, HAYA developed HTX-001, a targeted fibrosis-modifying therapy for heart failure.

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

Retrieved on: 
Monday, May 22, 2023
GDF11, Mouse, Endothelial dysfunction, Heart failure, TGF, Heart, PAH, Serum, ATS, Matrix metalloproteinase inhibitor, Cardiac fibrosis, SMAD, Pharmacokinetics, Woman, IL-6, Research, Part, Inflammation, Biomarker, American Thoracic Society, SMAD2, Administration, TAC, MARCO, Asilomar International Conference on Climate Intervention Technologies, Patient, Vascular remodelling in the embryo, Orthostatic hypertension, Therapy, Hypoxia, Conference, Endothelium, Safety, KROS, Pharmaceutical industry, Medical device, Extractive metallurgy, Vaccine, Trapping, Fibrosis

“We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year.

Key Points: 
  • “We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year.
  • The preclinical presentations demonstrate observed ligand selectivity of KER-012 and changes in inflammation and fibrosis in models of PAH and cardiovascular diseases.
  • Keros reported preliminary topline data from the Part 1 single ascending dose portion of the trial in May 2022, and additional preliminary clinical data from the Part 2 multiple ascending dose portion of the trial in September 2022.
  • HPAECs and HPASMCs were treated with activin A, GDF11, or bone morphogenetic protein 9 (“BMP9”) in the presence of KER-012.

HAYA Therapeutics Adds World-Leading Cardiologist and Dark Genome Pioneer to Advisory Boards

Retrieved on: 
Thursday, February 16, 2023
Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Other Science, Research, General Health, Hospitals, Genetics, Health Technology, Science, Clinical Trials, Cardiology, DNA, SA, Jordan University of Science and Technology, Cornell University, Scientist, Virus, Assistant, Molecular biology, RNA, SAB, OHSU, Division, Patient, Listeria monocytogenes non-coding RNA, Biochemistry, Oregon Health & Science University, University, Therapy, Amyloidosis, Cardiac fibrosis, Medical school, Hypertrophic cardiomyopathy, Genomics, School, Multimedia, Cardiovascular disease, Cancer, CAB, IND, Vaccine, Pharmaceutical industry, Medicine

HAYA Therapeutics, SA , a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Ahmad Masri, M.D., M.S.

Key Points: 
  • HAYA Therapeutics, SA , a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Ahmad Masri, M.D., M.S.
  • View the full release here: https://www.businesswire.com/news/home/20230216005353/en/
    Dr. Ahmad Masri, a Cardiologist and Physician Scientist at the Oregon Health & Science University’s Knight Cardiovascular Institute, has been named the newest member of HAYA Therapeutic’s Clinical Advisory Board.
  • (Photo: Business Wire)
    “The expansion of our advisors with Ahmad and Cedric, and the creation of our Clinical Advisory Board marks a significant milestone for HAYA,” said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics.
  • “HAYA has pioneered a novel approach of targeting disease drivers within the dark genome, and I’m looking forward to working with their team in identifying and understanding relevant clinically-translatable dark genome targets.”

Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022

Retrieved on: 
Monday, October 31, 2022
Fibrosis, Diabetic retinopathy, ARI, Quality of life, Government, Therapy, Diagnosis, Xi, Prevalence, Research, Private Securities Litigation Reform Act, Eye, Association, Forward-looking statement, Heart, U.S. Securities and Exchange Commission, Patient, Patent, Industry, Type 2 diabetes, CNS, PMM2-CDG, Diabetic cardiomyopathy, Company, Disease, GLOBE, Quality, Central nervous system, Ix, Intention, Nasdaq, NEW, COVID-19, Vii, Cardiac fibrosis, Development, Medical device, Pharmaceutical industry, Diabetes

AT-001 has been previously studied in a Phase 1/2 study in approximately 120 patients with type 2 diabetes, a subset of which had DbCM.

Key Points: 
  • AT-001 has been previously studied in a Phase 1/2 study in approximately 120 patients with type 2 diabetes, a subset of which had DbCM.
  • Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need.
  • The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart.
  • In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events.

Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference

Retrieved on: 
Friday, May 20, 2022
Research, FDA, Clinical Trials, Cardiology, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Heart failure with preserved ejection fraction, University of Texas Southwestern Medical Center, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Degenerative disease, U.S. Securities and Exchange Commission, European Society of Cardiology, Patient, NASDAQ, Therapy, Clinical trial, Cardiac fibrosis, COVID-19, Marketing, Gladstone Institutes, FDA, Securities Act of 1933, Securities Exchange Act of 1934, IND, Precision medicine, Industry, University, Heart failure, Drug Quality and Security Act, Security (finance), ESC, HDAC6, Investigational New Drug, Pharmaceutical industry, Tenaya

TN-301 (previously named TYA-11631) is a small molecule HDAC6 inhibitor initially being developed by Tenaya for the potential treatment of heart failure with preserved ejection fraction (HFpEF).

Key Points: 
  • TN-301 (previously named TYA-11631) is a small molecule HDAC6 inhibitor initially being developed by Tenaya for the potential treatment of heart failure with preserved ejection fraction (HFpEF).
  • HFpEF is one of the greatest areas of unmet need in heart disease with more than three million patients in the United States.
  • Tenaya expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the second half of 2022.
  • Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease.